Table 3. Mean LTG daily dose and concentrations in different inducer groups and their statistical significance versus patients in group A.
| Number of samples | LTG dose (mg/day) |
Significance (P) |
LTG concentration Mean±SD (μg/mL) |
Significance (P) |
|
|---|---|---|---|---|---|
| Group A: LTG monotherapy | 71 | 156.93±52.99 | -- | 3.97±2.06 | -- |
| CBZ as the only concomitant AED | 10 | 170.00±34.96 | 1.00 | 1.84±1.44 | 0.00 |
| OXC as the only concomitant AED | 14 | 171.40±48.89 | 1.00 | 3.11±1.80 | 0.74 |
| TPM as the only concomitant AED | 10 | 172.50±29.93 | 1.00 | 4.20±1.74 | 1.00 |
| CBZ + TPM as the concomitant AEDs | 5 | 150.00±53.03 | 1.00 | 0.64±0.33 | 0.00 |
AEDs: Antiepileptic drugs; LTG: Lamotrigine; CBZ: Carbamazepine; OXC: Oxcarbazepine; VPA: Valproic acid; TPM: Topiramate